CureVac AG, the most clinically ad-vanced mRNA company, today announced that the company will present at two upcoming international investor conferences: UBS 2017 Global Healthcare Confer-ence in New York, NY; and Bio€quity Europe in Paris, France.

Executives from CureVac will provide an overview of the company’s business, in-dustry-leading mRNA technology platform, and clinical-stage product pipeline during each presentation and will be available to participate in one-on-one meet-ings with investors who are registered to attend each conference.

Founded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The fully integrated biopharmaceutical Ccompa-ny has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the de-velopment of cancer therapies, prophylactic vaccines and molecular therapies.

Since its inception, strongly backed by SAP founder Dietmar Hopp’s dievini CureVac has received approximately $370 million (€355 million) in equity invest-ments including an investment of the Bill & Melinda Gates Foundation of $ 52million in 2015. CureVac has entered into various collaborations with multina-tional corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.
In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac started the establishment and construc-tion of industrial scale production facilities.